BIOSHIN
BioShin is a wholly owned subsidiary of Biohaven Pharmaceuticals, a public biotech company. BioShin is a clinical stage biopharmaceutical company focused on developing medicines. It has proven leadership from global industry and academic settings and a portfolio of innovative, late stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders.
BIOSHIN
Industry:
Biotechnology Health Care Life Science Pharmaceutical
Founded:
2013-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.bioshin.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
60 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Google Tag Manager Google Universal Analytics Font Awesome Mobile Non Scaleable Content Nginx
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Current Advisors List
Current Employees Featured
Founder
Investors List
OrbiMed
OrbiMed investment in Series A - BioShin
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series A - BioShin
Suvretta Capital Management
Suvretta Capital Management investment in Series A - BioShin
Surveyor Capital
Surveyor Capital investment in Series A - BioShin
Cormorant Asset Management
Cormorant Asset Management investment in Series A - BioShin
More informations about "BioShin"
BioShin - Org Chart, Teams, Culture & Jobs - The Org
View BioShin's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more. Explore. Iterate. Vision. Log in. Sign up. …See details»
BioShin Company Profile 2024: Valuation, Funding & Investors
BioShin General Information Description. Researcher and developer of late stage migraine and neurological disorder treatments. The company, as a wholly owned and operating subsidiary …See details»
BioShin - Products, Competitors, Financials, Employees, …
About BioShin. BioShin is a wholly-owned subsidiary of Biohaven Pharmaceuticals, a public biotech company based in New Haven, CT, USA (NYSE:BHVN). BioShin is a clinical-stage …See details»
Biohaven Announces Formation Of BioShin, A Wholly Owned Asia …
Nov 28, 2018 Other BioShin Management Team. ... She is a board member of BayHelix, a Chinese non-profit professional organization geared to the life sciences and healthcare …See details»
BioShin Limited Broadens Senior Leadership Team with
Apr 19, 2021 By bringing together promising assets and a diverse management team with international expertise, BioShin is growing a nimble organization with an entrepreneurial spirit …See details»
Bioshin Company Profile - Office Locations, Competitors ... - Craft
Bioshin has 5 employees at their 1 location and $60 m in total funding,. See insights on Bioshin including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
BioShin Limited Broadens Senior Leadership Team with Veteran …
Apr 19, 2021 David Chung joins BioShin as Chief Strategy Officer and Head of Business DevelopmentSHANGHAI, China, April 19, 2021 (GLOBE NEWSWIRE) -- BioShin Limited, …See details»
BioShin - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Sep 28, 2020: Series A - …See details»
BioShin Ltd. - BioCentury Company Profiles - BCIQ
Jul 8, 2021 BioShin Ltd. - BioCentury Company Profiles for the biopharma industrySee details»
BioShin Expands Senior Leadership Team: Sarah Lu Joins BioShin …
Jul 8, 2021 BioShin has a proven and established, late-stage portfolio from its strategic partner, U.S.-based Biohaven Pharmaceuticals Inc., and is poised to quickly launch novel medicines …See details»
Bioshin CEO and Key Executive Team | Craft.co
Bioshin's Director is David Wang. Other executives include Karl Lintel, Chief Executive Officer; John Donnie McGrath, President and Executive Chairman and 5 others. See the full …See details»
BioShin Expands Senior Leadership Team: Sarah Lu Joins
SHANGHAI, July 8, 2021 /PRNewswire/ -- BioShin Limited today announced the appointment of Dr. Zhihong (Sarah) Lu as Chief Medical Officer and Dr. Ma (Mary) Li as Chief Commercial …See details»
BioShin Expands Senior Leadership Team: Sarah Lu Joins BioShin …
SHANGHAI, July 8, 2021 /PRNewswire/ -- BioShin Limited today announced the appointment of Dr. Zhihong (Sarah) Lu as Chief Medical Officer and Dr. Ma (Mary) Li as Chief Commercial …See details»
BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A ...
Sep 28, 2020 NEW HAVEN, Conn. and SHANGHAI, Sept. 28, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN, "Biohaven") announced today that …See details»
BioShin Expands Senior Leadership Team: Sarah Lu Joins BioShin …
Jul 8, 2021 BioShin has a proven and established, late-stage portfolio from its strategic partner, U.S.-based Biohaven Pharmaceuticals Inc., and is poised to quickly launch novel medicines …See details»
BioShin Expands Senior Leadership Team: Sarah Lu Joins ... - AsiaOne
SHANGHAI, July 8, 2021 /PRNewswire/ -- BioShin Limited today announced the appointment of Dr. Zhihong (Sarah) Lu as Chief Medical Officer and Dr. Ma (Mary) Li as Chief Commercial …See details»
BioShin Limited Broadens Senior Leadership Team with Veteran
SHANGHAI, China, April 19, 2021 (GLOBE NEWSWIRE) -- BioShin Limited, biopharmaceutical company focused on the discovery, development and commercialization of novel, life …See details»
BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A ...
Sep 28, 2020 BioShin holds rights to the Biohaven portfolio for all of the Asia-Pacific Region, including Australia and New Zealand, excluding Japan. Biohaven is a majority shareholder in …See details»
BioShin enrolls first patient into an Asia-Pacific regional multi ...
SHANGHAI, China, Nov. 23, 2020 (GLOBE NEWSWIRE) -- BioShin Limited announced today that the first patients were enrolled in its regional multi-center study, BHV3000-310, being …See details»